Background: Maternal prenatal supplementation with folic acid and other vitamins has been inconsistently associated with a reduced risk of childhood acute lymphoblastic leukemia (all). little is known regarding the association with acute myeloid leukemia (aMl), a rarer subtype. Methods: We obtained original data on prenatal use of folic acid and vitamins from 12 case-control studies participating in the childhood leukemia international consortium (enrollment period: 1980-2012), including 6,963 cases of all, 585 cases of aMl, and 11,635 controls. logistic regression was used to estimate pooled odds ratios (Ors) and 95% confidence intervals (cis), adjusted for child's age, sex, ethnicity, parental education, and study center. Results: Maternal supplements taken any time before conception or during pregnancy were associated with a reduced risk of childhood all; odds ratios were 0.85 (95% ci = 0.78-0.92) for vitamin use and 0.80 (0.71-0.89) for folic acid use. the reduced risk was more pronounced in children whose parents' education was below the highest category. the analyses for aMl led to somewhat unstable estimates; Ors were 0.92 (0.75-1.14) and 0.68 (0.48-0.96) for prenatal vitamins and folic acid, respectively. there was no strong evidence that risks of either types of leukemia varied by period of supplementation (preconception, pregnancy, or trimester). Conclusions: Our results, based on the largest number of childhood leukemia cases to date, suggest that maternal prenatal use of vitamins and folic acid reduces the risk of both all and aMl and that the observed association with all varied by parental education, a surrogate for lifestyle and sociodemographic characteristics. (Epidemiology 2014;25: 811-822) 
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A cute leukemias are the most common cancers in children under 15 years of age; 80% are acute lymphoblastic leukemia (all), 17% acute myeloid leukemia (aMl), and 3% chronic myeloid leukemia. 1, 2 the incidence of all peaks in children 2-5 years old, whereas the incidence of aMl is constant across ages. 1, 2 the early onset of leukemia is suggestive of genetic predisposition and critical exposures occurring before and during pregnancy. Prenatal supplementation with folic acid and other vitamins, known to maintain Dna integrity 3 and reduce oxidative stress, 4, 5 could play a role in the prevention of childhood leukemia. the risk of childhood all following maternal folic acid or vitamin intake before and during pregnancy has been studied previously but results have been inconsistent. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] this may be because of different underlying genetic susceptibilities in the studied populations, temporal variations in folic acid and vitamin intake over study periods, and limited statistical power of individual studies. Meta-analyses of published results reported a reduced (although imprecise) risk of all associated with maternal use of vitamins during pregnancy, but not before conception. 7, 8, 10 little is known about the risk of aMl in relation to maternal supplementation with folic acid or vitamins [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] to overcome the limitations of previous studies, we pooled original data on prenatal intake of folic acid and vitamins from 12 case-control studies participating in the childhood leukemia international consortium 18 and examined the associations with childhood all (overall and by immunophenotype) and aMl. We also evaluated the modifying effects of education level as a marker of socioeconomic status and nutritional status, [19] [20] [21] [22] [23] and of alcohol consumption, which is known to modify folate metabolism. 24 
METHODS

Study Population
twelve case-control studies conducted in 10 countries from 1980 to 2012 and participating in the childhood leukemia international consortium 18 contributed data to the current pooled analyses (table 1); this included 8 studies with published data from australia, 10 canada, 14 France, 6 germany, 13 new Zealand, 7 and the United States 9,16,17 and 4 studies from Brazil, costa rica, egypt, and greece with unpublished data at the time of this report. Study design and characteristics of participants in individual studies have been described previously. 18 a total of 19,183 children were available for analysis (6, 963 cases of all, 585 cases of aMl, and 11,635 controls). information on immunophenotype was available for 84% of all, including 5,193 children diagnosed with the precursor B-cell type and 678 with the t-cell type.
Data Collection and Standardization
the participating childhood leukemia international consortium studies provided original data on self-reported maternal supplementation with folic acid and other vitamins up to 1 year before conception and during pregnancy. information on the type and period of supplementation included (1) use of dietary supplements, which may have contained folic acid or not, (2) use of specific vitamins such as folic acid, vitamin c, vitamin D, or others, (3) supplementation taken at any time during the prenatal period (referred to as "any time"), and (4) supplementation taken in a specific time period (preconception or during pregnancy-as a whole or by trimester). We also obtained data on leukemia subtypes; the child's race/ethnicity, sex, and age (at diagnosis for cases and corresponding age for controls participating in age-matched studies or age at enrollment/interview); birth weight; mother's age at delivery; maternal and paternal education level; and maternal alcohol consumption. the availability of data on maternal supplement use by type and period, for each participating study and overall, is summarized in table 1. twelve studies provided data on vitamin supplementation any time before or during pregnancy (98% complete), whereas 7 studies provided data specific to supplementation with folic acid during pregnancy, representing data for 47% of all study subjects.
Data were checked in collaboration with the principal investigators of each study and were standardized across studies for the pooled analyses. in particular, the standardized variable for use of any vitamins included women who reported single vitamins or multivitamins, regardless of whether they contained folic acid; the use of mineral supplements such as iron was not taken into consideration. Women who specifically reported taking folic acid were included in the group "folic acid." time-specific variables were created for maternal supplementation with any vitamins any time prenatally, and specifically for use preconception, during pregnancy, and by trimesters. identical time-specific variables were created for maternal intake of folic acid. Other variables with heterogeneous definitions across studies were classified into the following categories for ethnicity (White/caucasian/european vs. other) and highest level of parental (father or mother) education (none or primary, secondary, and tertiary-the latter generally meaning some university education).
For each study, we obtained the approximate year when food fortification with folic acid was recommended or implemented. this information was either publicly available or provided by the investigators of the participating studies. Based on the year of birth, we assigned for each child a value for being born before or after folic acid fortification.
Statistical Analyses
Study-specific and pooled odds ratios (Ors), as well as approximate 95% confidence intervals (cis), were estimated from unconditional logistic regression models, separately for all and aMl, and by immunophenotype for all (B-and t-cell lineage). all variables except mother's age at delivery, child's age at diagnosis (and corresponding age for controls), and birth weight were categorical. Models were adjusted for child's age, sex, ethnicity, and parental education level, as these variables were either matching factors in the individually matched studies or treated as confounders. We present models without and with adjustment for study center (Models 1 and 2, respectively) for the main analyses on use of vitamin/folic acid supplements any time, preconception, and during pregnancy; only study-adjusted models (Model 2) are presented for additional analyses. Overall, adjusting for study center improved the fit of all models (P values for log-likelihood ratio test <0.001). Other variables (child's birth weight, maternal age at delivery, maternal alcohol intake, and child born before/after folic acid food fortification) were not included in the final models, as the Ors changed by less than 10%. We conducted stratified analyses by sex, age at diagnosis (infants 0-1 year vs. older children), parental education (none/ primary, secondary, and tertiary), maternal alcohol consumption (drinkers vs. nondrinkers), and folic acid food fortification (child born before vs. after). P values for heterogeneity between strata were obtained from the log-likelihood ratio test or Woolf's test. in order to characterize the heterogeneity in vitamin and folic acid supplementation between participating childhood leukemia international consortium studies and to account for it in the analysis, we assessed between-study and withinstudy variability. total variability N p (1-p) was partitioned into between-study variability (which represents the deviation of study-specific prevalence from the mean prevalence for all studies combined, weighted by the number of subjects in individual studies,
) 2 ) and within-study variability (which represents the deviation of individual subjects from the study-specific mean prevalence, weighted by the number of subjects in their corresponding study, V W = n p (1-p )
, where N is the total number of cases and controls across all studies, n is the total number of subjects in each study, p is the proportion of women taking vitamins across all studies, and p i is the proportion of women taking vitamins in each study. For use of vitamins and folic acid any time and during pregnancy, V B accounted for approximately 33% to 44% of the total variability, whereas for preconception vitamin and folic acid intake V B accounted for about 16% of the total variability. Subsequently, we grouped the study sites into those contributing to either the lowest between-study variability (V B < 30% of total variability) or the highest between-study variability (V B ≥ 30% of total variability) and conducted stratified analyses for each group to assess the impact of study heterogeneity in Models 1 versus 2. the cut point for grouping studies with low versus high V B was driven by the data. lastly, we conducted sensitivity analyses by systematically excluding 2 studies (out of 12) at a time, which resulted in 66 sets of 10 studies. For each set, we then computed the Ors and 95% cis for each type and period of maternal supplementation. Out of a total of 66 Ors, we calculated the minimum, mean and maximum Ors, and the corresponding 95% cis.
RESUlTS
the distribution of sociodemographic characteristics among cases and controls in the pooled dataset is shown in table 2. the percentages of mothers reporting vitamin supplementation before and during pregnancy varied considerably by country and by study period (Figure 1 ). Between 1% and 39% of mothers reported taking vitamins before pregnancy, whereas use during pregnancy ranged from 9% to 95%; vitamin use during pregnancy was most common in north america, costa rica, and australia and least common in Brazil, France, germany, and new Zealand. Between-study differences were also observed for maternal intake of folic acid in the subset of studies where this information was available ( Figure 2 ). the Pearson correlation coefficients between maternal supplementation before conception and during pregnancy were 0.28 for vitamins and 0.23 for folate.
Childhood All
the adjusted study-specific Ors for risk of all associated with maternal intake of vitamins any time prenatally ranged from 0.44 (95% ci = 0.26-0.77) in costa rica to 1.18 (0.65-2.14) in Brazil (table 3) . the study-specific Ors for vitamin supplementation preconception and during pregnancy also varied across studies (etable 1, http://links.lww.com/ eDe/a806). table 4 shows the results of the pooled analyses for type and period of maternal supplementation for all. the Ors for maternal supplementation any time prenatally, with no adjustment for study center, were 1.21 (1.13-1.28) for vitamins and 1.09 (0.99-1.19) for folic acid (table 4, Model 1). in contrast, the analyses with adjustment for study center showed that maternal intake of vitamins and folic acid at any time was associated with a reduced risk of all in the offspring, with pooled Ors of 0.85 (0.78-0.92) and 0.80 (0.71-0.89), respectively (table 4, Model 2). there was no evidence that the magnitude of the association between all and prenatal vitamin or folic acid supplementation varied by period of use, that is, preconception and pregnancy (table 4) or by trimester (table 5) . the impact of adjustment for study on the pooled Ors for supplementation at any time and during pregnancy was stronger in the group of studies contributing to high between-study variability compared with those contributing to low betweenstudy variability. Sensitivity analyses removing 2 studies at a time showed that the minimum, mean, and maximum studyadjusted Ors remained below 1.0 for each type and period of supplementation (eFigure 1, http://links.lww.com/eDe/ a806). the findings for vitamins use based on the 7 studies with folic acid data were very similar to those using the full set of 12 studies presented in table 4 (data not shown).
the magnitude of the associations with vitamin and folic acid intake was similar for B-and t-cell precursor all (table 6) . the reduction in risk associated with folic acid intake any time prenatally was stronger for children whose parents had no formal or primary education (Or = 0.47 [0.33-0.68]) compared with those with secondary education (0.73 [0.59-0.90]) and tertiary education (0.96 [0.82-1.12]; P for interaction = 0.01) ( levels was observed for vitamin intake (P for interaction = 0.14). also, a reduction in risk was somewhat stronger for children whose mothers reported not drinking alcohol compared with those drinking alcohol; the 95% cis, however, overlapped between strata (table 6) . Mothers drinking alcohol were more likely to have tertiary education (54%) than none/primary (12%) or secondary (34%) education. Stratified analyses for children born before or after folic acid food fortification did not reveal substantial differences in Ors (with major overlap of the 95% cis) (table 6). all stratified analyses were also conducted separately for supplement use preconception and during pregnancy (etable 2, http://links.lww.com/ eDe/a806). the results for the various strata were similar for use during pregnancy, whereas those for the preconception period were less consistent; for example, there was a tendency for lower risk estimates associated with preconception vitamin and folate supplementation for children born after folic acid food fortification compared with use before fortification (etable 2, http://links.lww.com/eDe/a806). the reductions in risk after folic acid supplementation appeared stronger in infants and boys, although these observations were consistent with chance variation (data not shown).
Childhood AMl
the study-specific Ors estimating the risk of childhood aMl associated with maternal intake of vitamins any time ranged from 0.26 (95% ci = 0.09-0.79) in costa rica to 1.13 (0.75-1.70) in Brazil (table 3) . the study-specific Ors associated with supplementation preconception and during pregnancy also varied across studies (etable 3, http://links.lww. com/eDe/a806). table 7 shows the results of the pooled analyses for type and period of maternal supplementation, without and with adjustment for study center (Model 1 and Model 2, respectively). Just as in the analyses for all, the impact of adjustment for study center on the pooled Ors for aMl was stronger in the group of studies with high between-study variability compared with those with low between-study variability. the study-adjusted pooled Ors associated with vitamin and folic acid supplementation at any time were 0.92 (0.75-1.14) and 0.68 (0.48-0.96), respectively (table 7, Model 2). the reduction in risk appeared stronger for maternal intake of folic acid during pregnancy (0.52 [0.31-0.89]) compared with preconception (0.88 [0.59-1.32]), although the 95% ci intervals overlapped; there was no evidence that the risk of aMl associated with vitamin intake varied by period of use (table 7, Model 2). Sensitivity analyses for supplementation with folic acid showed that the mean Ors for aMl remained below 1.0; however, maximum Ors and most upper limits of the 95% cis were above 1.0, indicating that the results may be unstable (eFigure 2, http://links.lww.com/eDe/a806). also, the Model 2 Ors using data from the 7 studies with folic acid data were 0.74 (0.53-1.05) and 0.65 (0.43-1.00) for vitamin use any time and during pregnancy, respectively (not shown); these were lower than the Ors from the analysis using the full set of 12 studies (table 7). note that the same 7 studies provided data for vitamins and folate preconception. the sample size was insufficient for meaningful stratified analyses.
DISCUSSION
although acute leukemia is the most common cancer in children, it is a relatively rare disease, making it difficult to investigate possible risk factors. this large international collaborative study, which includes over 7,000 children diagnosed with acute leukemia and 11,000 controls, found moderate reductions in risk of all following maternal intake of vitamin and folic acid supplements before or during pregnancy. Similarly, a reduced risk of aMl was observed with folic acid use before or during pregnancy; results for vitamins were inconclusive. there was no strong evidence that the risks for either type of leukemia varied by period of supplementation (preconception, pregnancy, and trimester). Stratified analyses revealed possible differences in risk by parental education, a crude indicator of dietary quality. Previous individual case-control studies have reported inverse 6, 15 or null 7, 10, 14 associations between maternal folic acid supplementation during pregnancy and childhood all, as well as inverse, 6, 7, 13, 16 null, 10, 14 or positive 11 associations with any vitamins or with multivitamins. regarding supplementation during the preconception period, reduced risks have been associated with folic acid, 9, 10 whereas results have been inconsistent for any vitamins or multivitamin intake. [9] [10] [11] [12] 16 these studies were generally limited by small numbers of leukemia cases. also, some of them were conducted in affluent populations with high intakes of folate from dietary and supplemental sources, leading to low exposure variation and limited power to uncover the alternative hypothesis. three meta-analyses including small numbers of published studies (2-5 studies) on childhood all suggested a protective effect for prenatal vitamins, 8, 10 but not for folic acid. 7,10 as for childhood aMl, only a few studies have been conducted to date: null results or moderately decreased risks were reported for maternal supplementation with vitamins "before and during pregnancy" 6, 11, 13 and with folic acid use. 6 to address the limitations of previous studies on childhood acute leukemias, we pooled original data from 8 published studies from northern america, europe, and Oceania 6, 7, 9, 10, 13, 14, 16, 17 and 4 unpublished studies (most from developing countries). Most participating studies provided detailed information on type and period of prenatal supplementation, alcohol consumption, and disease classification. Data from 2 studies in the United States, 1 including 56 children with all 12 and the other limited to children with Down syndrome diagnosed with all and aMl, 11 were not included in our analyses; however, this likely had no tangible impact on our results. Moreover, consistent with our findings, both studies reported decreased risks of childhood all associated with prenatal maternal vitamin intake. 11, 12 although standardizing data across studies may introduce nondifferential misclassification of exposure (and may underestimate the risk), pooling data from countries with different socioeconomic backgrounds provides substantial variation in vitamin use, therefore probably increasing the opportunity to detect associations overall.
Previous analyses pooling original data from observational studies or clinical trials have adjusted for study center to account for measured and unmeasured (or unidentifiable) differences in designs and backgrounds 25 or have conducted meta-analyses with published results using fixed or random effect models. [25] [26] [27] in our pooled analyses, the inclusion of study center as a variable in the logistic regression models had a substantial impact on all risk estimates. this was especially true for studies exhibiting the largest heterogeneity in vitamin/folic acid use; however, other study characteristics could not be identified as possible sources of heterogeneity. also, adjusting for study center substantially improved the goodness of fit of the models. the sensitivity analyses excluding individual studies indicated that the results for childhood all were robust for supplementation at any time and during pregnancy, and to a lesser extent before conception. results for aMl were less precise overall because of small numbers. results from meta-analyses were consistent with the studyadjusted pooled analyses for all types and periods of interest except the preconception period, for which we have the least data (data not shown). therefore, we chose to present only the results of pooled analyses of individual data, as this method allows for a transparent evaluation of the possible impact of study heterogeneity on the risk estimates, and provides more flexibility to assess subgroup and modifying effects, as well as goodness of fit of the models. Beginning in the 1990s, folic acid supplementation was recommended before conception and during early pregnancy because of its role in preventing neural tube defects. 8 Multivitamins containing folic acid were later recommended for the additional benefit of preventing a larger spectrum of birth defects and perinatal conditions. 8 Folic acid is the synthetic form of folate, which is involved in Dna synthesis, repair, and methylation, 3 whereas vitamins such as c and D are known to prevent oxidative stress, 4,5 thus playing a critical role against carcinogenesis. low folate levels have been associated with increased risk of colorectal cancer and possibly other solid cancers in adults; however, the association between high-dose folic acid supplementation and increased cancer incidence remains controversial. [28] [29] [30] [31] [32] the approximate calendar periods during which the use of folic acid was first recommended spanned from 1992 to 2002 in the countries that we studied (table 1) . Furthermore, the recommendations varied over time and by country, including differences in dosage (0.36 mg to 0.8 mg per day), time windows (periconception/early pregnancy or throughout pregnancy), schedule (daily or weekly), and the composition of multivitamins. 8 Similarly, fortification of grain products with folic acid was introduced at different calendar periods across countries. 33 Detailed information on dietary and supplementary sources of folate was not available in most participating studies, and therefore could not be directly accounted for in our analyses; however, adjusting for study center likely accounted for some geographical, temporal, and social differences.
in our study, supplementation with any vitamins and folic acid any time prenatally was associated with a 15% and 21% reduction in childhood all risk, respectively, suggesting that vitamins other than folic acid are unlikely to contribute to additional risk reduction. the interpretation of these findings should take into consideration that folic acid intake is likely to be more specific compared with vitamins, which is a more heterogeneous exposure variable. in contrast, for childhood aMl, folic acid intake was associated with a 32% reduction in risk, whereas no persuasive decreased risk was seen with vitamin intake. the observed difference in aMl risk by type of supplementation may be because of chance. information on doses of folic acid and other vitamins was not available for most studies; however, taking vitamins or folic acid throughout the pregnancy seem to be important in preventing childhood all, rather than supplementation targeted in early pregnancy, as originally indicated for preventing neural tube defects.
We found that the reduced risk of childhood all and aMl associated with prenatal supplementation, especially with folic acid, was more pronounced in families with lower education levels. in our study, the lower prevalence of alcohol consumption (a known folate antagonist) observed among mothers with lower education levels may have contributed to these observations. Overall, mothers with low education were less likely to use prenatal supplementation and to have given birth after food fortification with folic acid; this was true for both cases and controls (data not shown). also, parental education may have been a surrogate for other unmeasured lifestyle and sociodemographic variables. alternatively, differential maternal recall or genetic background within individual study populations may have contributed to differential leukemia risks by education. although the distribution of education levels by case-control status varied among participating studies (ie, lower education in cases vs. controls in 8 studies, lower education in controls vs. cases in 2 studies, and no difference between cases and controls in 3 studies), it is difficult to anticipate the impact on the overall pooled risk estimates. the majority of infants with leukemia present rearrangements of the mixed lineage leukemia (Mll) gene located at chromosome 11q23, which may result from targeted insults by specific dietary and environmental agents. 34, 35 Our stratified analyses by age at diagnosis were inconclusive. null findings have been previously reported between prenatal vitamin intake and infant leukemia risk, with the possible exception of those with the Mll+ gene fusion. 36 also, a reduced frequency of the low-function variant of the 5,10-methylenetetrahydrofolate reductase (MtHFr) gene (c677t) was reported in all/Mll+ infants compared with cord blood samples. 37 Our research consortium is working toward obtaining and validating data on cytogenetic and molecular characterization of leukemia cases across studies in order to perform these subtype-specific analyses.
in conclusion, taking into consideration both strengths (inclusion of published and unpublished data, large sample size for main and subgroup analyses, diversity in exposures, and ability to conduct sensitivity analyses) and limitations (lack of specificity in type and dose of vitamins and other minerals, possible recall and selection biases in individual studies), the results of our pooled analyses indicate that maternal prenatal supplementation with vitamins or folic acid reduced the risk of childhood all. Furthermore, we found that education, as a crude surrogate for lifestyle and sociodemographic characteristics, may modify the magnitude of the associations. limited data for childhood aMl also suggest that maternal supplementation with folic acid, but not vitamins, reduces the risk of this rarer subtype.
